No Data
No Data
As of July 19, 2024, there are 12,820 shareholders of Jinkai Life Sciences (301509.SZ) Company.
On July 23rd, Gelunhui reported that as of July 19th, 2024, there were 12,820 shareholders in Jinkai Life Science (301509.SZ) according to the investor communication platform.
Jinkai Life Science (301509.SZ): currently, the proportion of unrestricted circulating shares is 25%, and it does not meet the repurchase requirements.
On July 19th, Gelunhui reported that Jinkai Life Science (301509.SZ) stated on the investor interaction platform that the company's unrestricted circulating shares accounted for 25% and did not have the conditions for repurchase. However, the company has always attached importance to returning shareholders. We will closely monitor market dynamics, comprehensively evaluate the company's financial and cash flow status, and future global strategic development needs. If the company has a corresponding plan to repurchase shares in the future, we will fulfill our disclosure obligations in a timely manner.
Jinkai Life Sciences (301509.SZ) is a "intermediate supplier" of SNAC, an oral permeation enhancer for Simeglestat.
On July 3, Gelunhui reported that an investor asked Jinkai Life Science Technology (301509.SZ) on the investor interaction platform, "Is it true that Jinkai will have intentions to manufacture Meaglu peptide for Novo Nordisk?" The company replied that the company is an intermediate supplier of SNAC, an oral permeation enhancer for Meaglu peptide. Please refer to the company's announcement for relevant information about the company. Do not believe rumors and unofficial information.
A-share noon review: Shanghai Composite Index fell 0.39%. Water conservancy and brain-computer interface concepts saw the largest increase, while the semiconductor sector adjusted.
As of the noon closing, the Shanghai Composite Index fell 0.39% below 3000 points, the Shenzhen Component Index fell 0.4%, and the Chinext Price Index fell 0.89%.
Jinkai Bioscience (301509.SZ): Continuously paying attention to the application of synthetic biology technology in the industry.
Jinkai Life Sciences (301509.SZ) stated on the investor interaction platform on June 18th that the company is continuously paying attention to the application of synthetic biology technology in the industry, but currently the company has not carried out substantial research and practical application of related technologies.
Jin Kai Shengke (301509.SZ): Currently, the cooperation with Eli Lilly does not involve diet medicine programs
Gelonghui, May 28 | Jinkai Shengke (301509.SZ) said on the investor interactive platform that the company's current cooperation with Eli Lilly does not involve diet medicine projects. The company always actively monitors customer business developments and strives to expand and promote business in line with its own development.
No Data